Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Janux Therapeutics Inc (JANX), Cytokinetics (CYTK) a...

Analysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Cytokinetics (CYTK)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Janux Therapeutics Inc today and set a price target of $22.00. Stranah...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JANX	$15.85	-1.55%	689.02K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JANX	$15.85	-1.6%	689.02K
3
4
5
6

JANX

JANX

Get Janux Therapeutics, Inc. Data in Excel

Get Janux Therapeutics, Inc. Data in Excel